MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization productsJohn V. Duncia, Richard E. Olson, William J. Pitts et al.|Bioorganic & Medicinal Chemistry Letters|1998Cited by 406
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4E. Scott Priestley, Anne Marinier, Laurence Dubé et al.|Journal of Medicinal Chemistry|2022Cited by 27
Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial ThrombosisX. Zhang, E. Scott Priestley, Ruth R. Wexler et al.|Journal of Medicinal Chemistry|2024Cited by 12
Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart FailureJeremy M. Richter, E. Scott Priestley, Ruth R. Wexler et al.|Journal of Medicinal Chemistry|2024Cited by 7
Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa InhibitorsJeremy M. Richter, E. Scott Priestley, Daniel L. Cheney et al.|ACS Medicinal Chemistry Letters|2016Cited by 6